Nonalcoholic Steatohepatitis and Endpoints in Clinical Trials.
Nonalcoholic fatty liver disease (NAFLD) is now the leading cause of liver disease in developed countries, and the rates of NAFLD continue to rise in conjunction with the obesity pandemic. While the majority of patients with isolated steatosis generally have a benign course, a diagnosis of nonalcoho...
| Publicado en: | Gastroenterology & Hepatology Vol. 12; no. 12; pp. 756 - 764 |
|---|---|
| Autores principales: | , , |
| Formato: | tables/charts Journal Article |
| Publicado: |
Gastro-Hep Communications, Inc
Dec2016
|
| Acceso en línea: | Ver este registro en EBSCOhost |